Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury

Yajing Wang, Wayne Bond Lau, Erhe Gao, Ling Tao, Yuexing Yuan, Rong Li, Xiaoliang Wang, Walter J. Koch, and Xin-Liang Ma

1Department of Emergency Medicine, 2Center for Translational Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania; and 3Department of Cardiology, Xijing Hospital, Xian, Peoples Republic of China

Submitted 4 November 2009; accepted in final form 18 December 2009

Wang Y, Lau WB, Gao E, Tao L, Yuan Y, Li R, Wang X, Koch WJ, Ma XL. Cardiomyocyte-derived adiponectin is biologically active in protecting against myocardial ischemia-reperfusion injury. Am J Physiol Endocrinol Metab 298: E663–E670, 2010. First published December 22, 2009; doi:10.1152/ajpendo.00663.2009.—Adiponectin (APN) is traditionally viewed as an adipocyte-specific hormone with anti-inflammatory, anti-oxidative, and anti-nitrative cardoprotective effects. However, new research has demonstrated that APN is also expressed in cardiomyocytes, and its production is increased by activation of peroxisome proliferator-activated receptor-γ (PPARγ) (4, 11, 22). However, whether this cardiomyocyte-derived APN is biologically active in protecting against SI/R injury is unknown. Therefore, the aims of the present study were to determine whether cardiomyocyte-derived APN is biologically active and cardioprotective and, if so, to further investigate transmembrane and intracellular signaling mechanisms responsible for the cardioprotective actions of locally produced APN.

Adiponectin (APN) is a protein hormone circulating in plasma as multimeric complexes at relatively high concentration (2–10 μg/ml) (21). Besides its well-defined insulin sensitization and metabolic regulatory effects, recent experimental and clinical studies demonstrate that APN is a potent endogenous cardioprotective molecule (10). Numerous epidemiological studies have shown that reduced APN levels correlate with increased risk of cardiovascular disease in obesity and diabetes (9, 12, 16, 29); high plasma APN concentrations are associated with a lower risk of myocardial infarction (MI) in men (23). In addition, recent clinical observations have demonstrated that post-MI plasma APN levels correlated positively with myocardial salvage index and ejection fraction recovery (24). Persistently low plasma APN concentrations after acute MI are predictive of future adverse cardiac events (1). As such, reduced APN production has been recognized as a risk factor for cardiovascular disease, and enhancing APN production has been accepted as a potential therapeutic modality for ameliorating diabetic cardiovascular injury.

Although APN receptors, including APN receptor 1 (AdipoR1) and APN receptor 2 (AdipoR2), are present in most organs, including adult cardiomyocytes, it was generally accepted until recently that APN is exclusively synthesized in adipocytes. However, new studies reveal that APN gene is expressed in other cell types, including hepatocytes, myotubes, skeletal muscle, and osteoblasts (17, 25). Three recent studies have demonstrated that APN is also expressed in adult cardiomyocytes, and its production is increased by activation of peroxisome proliferator-activated receptor-γ (PPARγ) (4, 11, 22). However, whether this cardiomyocyte-derived APN is biologically active, contributing to physiological and pathological regulation of cardiomyocyte function, remains completely unknown presently. Addressing this critical question may provide clues to the largely unknown regulation of cardiomyocyte metabolism and function in the diabetic heart.

Therefore, the aims of the present study were to determine whether cardiomyocyte-derived APN is biologically active and cardioprotective and, if so, to further investigate transmembrane and intracellular signaling mechanisms responsible for the cardioprotective actions of locally produced APN.

MATERIALS AND METHODS

Animals. Adult male C57BL/6, homozygous adiponectin knockout (APN-KO), AdipoR2 homozygous knockout (AdipoR2-KO), and their littermate wild-type (WT) control weighing 27–32 g were purchased from Jackson Laboratories (Bar Harbor, ME). All procedures were performed in accordance with the National Institutes of
E664

CARDIAC ADIPONECTIN AND MYOCARDIAL PROTECTION

Health Guidelines on the Use of Laboratory Animals and were approved by the Thomas Jefferson University Committee on Animal Care.

In vivo small-interfering RNA-mediated AdipoR1 knock down. AdipoR1 knockout mice were not commercially available when this study was performed. We thus utilized the small-interfering RNA (siRNA) gene silencing technique to knock down AdipoR1 expression in mouse heart (AdipoR1-KD). In brief, three predesigned AdipoR1-specific siRNA (catalog nos.: s91209, s91210, and s91208; Ambion Silencer) or control nonspecific siRNA oligos (Silencer Select Negative Control no. 1 siRNA; Ambion) were diluted in 5% glucose and mixed with in vivo jet PEI (polyethyleneimine; Genesee Scientific, San Diego, CA). Adult WT or AdipoR2-KO mice were anesthetized with 2% isoflurane, and the heart was exposed via a left thoracotomy at the fifth intercostal space. siRNA (20 µl; 0.8 µg/µl) or negative control was delivered via three separate intramyocardial injections (32.5-gauge needle) to temporarily Blanch the left ventricular free wall. Based on our pilot experiments showing that AdipoR1 expression reaches its nadir 48 h after siRNA injection, hearts were isolated 48 h following siRNA treatment for adult cardiomyocyte harvest and preparation as described below.

Preparation and culturing of adult mouse cardiomyocytes. Myocytes were anesthetized with 2% isoflurane. Hearts were removed and perfused at 37°C for ~3 min with a Ca²⁺⁻free bicarbonate-based buffer. Enzymatic digestion was initiated by adding collagenase type B/D to the perfusion solution. After ~3 min of digestion, at which point the cardiac tissue became firm and swollen, 50 µM Ca²⁺ was added to the enzyme solution; ~7 min later, the left ventricle was removed, cut into several sections, and further digested in a shaker for 10 min at 37°C in the same enzyme solution. The supernatant containing the dispersed myocytes was filtered in a sterilized tube and centrifuged at 800 g for 1 min. The cell pellet was then resuspended in bicarbonate-based buffer containing 125 µM Ca²⁺. After the myocytes were pelleted by gravity for ~10 min, the supernatant was aspirated, and the myocytes were resuspended in bicarbonate-based buffer containing 250 µM Ca²⁺. Myocytes were plated at 0.5–1 × 10^6 cells/cm² in culture dishes precoated with mouse laminin.

Simulated ischemia-reperfusion. After 1 h of culture in a 5% CO₂ incubator at 37°C, cardiomyocytes were randomized to receive either vehicle or rosiglitazone treatment (RSG, 10 µM) for 48 h following siRNA treatment for adult cardiomyocyte harvest and preparation as described above.

Measurement of caspase-3 activity. Apoptotic cell death was determined by caspase-3 activation, via a fluorometric kit (R&D System, Minneapolis, MN). Briefly, cardiomyocytes were harvested using culture lysis buffers (50 mM HEPES, pH 7.4, 0.1% Chaps, 5 mM dithiothreitol, 0.1 mM EDTA, and 0.1% Triton X-100). Cell lysates samples (50 µg) were used to perform the fluorometric assay per the manufacturer’s instructions. The fluorescence emission of the 7-amino-4-trifluoromethyl-coumarin (AFC), released on proteolytic cleavage of the fluorogenic substrate DEVD-AFC by active caspase-3, was measured using a Biotek FL600 microplate fluorescence reader (excitation wavelength, 400 nm; emission wavelength, 505 nm). Caspase-3 activity was expressed as mmol AFC per hour per milligram protein.

Lactate dehydrogenase release assay. At the end of observation period, conditioned media was collected, and cells were lysed. Lactate dehydrogenase (LDH) activity in conditioned media and cell lysates was determined spectrophotometrically (SpectraMax-Plus microplate spectrophotometer; Molecular Devices, Sunnyvale, CA). The percentage of LDH release was calculated as follows: (A-B)/(C-B) × 100, where A is LDH activity in conditioned media, B is LDH activity in culture media (without cells), and C is LDH activity in cell lysates.

Quantification of cellular nitrotyrosine content. Cardiomyocyte nitrotyrosine content, an index of nitric oxide inactivation by superoxide and oxidative/nitrative stress, was determined by nitrotyrosine content, an index of nitric oxide inactivation by superoxide and oxidative/nitrative stress, was determined by nitrotyrosine ELISA kit (Cell Sciences, Canton, MA) per the manufacturer’s instructions.

Statistical analysis. All values in the text and Figs. 1–7 are presented as means ± SE of n independent experiments. All data (except Western blot density) were subjected to ANOVA followed by Bonferroni correction for post hoc t-test. Western blot densities were analyzed with the Kruskal-Wallis test followed by Dunn’s post hoc test. Probabilities of 0.05 or less were considered to be statistically significant.

RESULTS

Lack of APN, but not its receptors, significantly increased SI/R injury. Cardiomyocytes from adult male WT, APN-KO, AdipoR1-KD, and AdipoR2-KO mice were subjected to sham SI/R culture, or 3 h SI plus 12 h reperfusion. Cellular injury was determined by LDH release and caspase-3 activation. As shown in Fig. 1, SI/R caused significant LDH release and caspase-3 activation in all groups studied (P < 0.01 vs. respective sham control). Lack of APN (APN-KO) signifi-
Significantly increased SI/R injury, as evidenced by a higher percentage of LDH release (Fig. 1A, second group, $P < 0.05$ vs. WT) and greater caspase-3 activity (Fig. 1B, second group, $P < 0.01$ vs. WT). No significant difference in SI/R injury was observed between WT and APN receptor-deficient cardiomyocytes ($P > 0.05$), although LDH release and caspase-3 activation were slightly higher in cardiomyocytes from AdipoR1-KD/AdipoR2-KO mice. These results indicate that the basal level of APN produced by adult cardiomyocytes is biologically active in protecting cardiomyocytes against SI/R injury.

A PPARγ agonist regulates cardiomyocyte APN and its receptors' expression. To better understand the biological function of locally produced APN, cardiomyocytes were treated with RSG, a PPARγ agonist known to stimulate APN expression and secretion in adipocytes. Based on our pilot time-course observation, APN mRNA/protein expression, APN protein secretion, AdipoR1, and AdipoR2 protein expression was determined 6 h after RSG treatment. As summarized in Fig. 2, treatment of WT cardiomyocytes with RSG caused a 1.9-fold increase in APN mRNA expression, 2.7-fold increase in APN protein expression, and 1.6-fold increase in APN level in culture medium ($P$ values for all $< 0.01$). These results demonstrated that cardiomyocyte APN expression (at both the mRNA and protein level) and secretion are regulated by the PPARγ system.

The adult cardiomyocytes used in this study have no adipocyte contamination as determined by Oil red staining (data not shown). To further enhance our confidence that PPARγ-stimulated APN production is of cardiomyocytes origin, H9C2 cells (rat cardiac cell line) were treated with vehicle or RSG for 6 h. Comparable to that seen in adult cardiomyocytes, treatment of H9C2 cells also significantly increased APN mRNA.
expression (1.78 ± 0.24 over vehicle group, \( P < 0.01 \)), APN protein expression (2.51 ± 0.31 over vehicle group, \( P < 0.01 \)), and APN level (1.71 ± 0.22 over vehicle group, \( P < 0.01 \)) in culture medium.

To gain more insight into PPAR\( \gamma \) regulation of cardiac APN systems, additional experiments were performed to determine the effect of RSG on APN, AdipoR1, and AdipoR2 expression in WT cardiomyocytes and gene-manipulated cardiomyocytes. As expected, APN expression was not detected in APN-KO cardiomyocytes; the response to RSG was completely lost in these cells (Fig. 3, second group). The AdipoR1-KD or AdipoR2-KO condition alone neither altered basal cardiomyocyte APN production nor their response to RSG (Fig. 3, third and fourth group). However, basal APN expression was significantly increased in AdipoR1-KD/AdipoR2-KO cardiomyocytes (\( P < 0.05 \)), and the RSG response was significantly potentiated in these cells (Fig. 3, last group, \( P < 0.01 \)).

RSG treatment significantly increased AdipoR1 expression in WT cardiomyocytes (Fig. 4, first group), and lack of APN neither altered basal AdipoR1 expression nor its response to RSG (Fig. 4, second group). Our method of intramyocardial siRNA delivery was highly successful. Basal AdipoR1 expression was markedly inhibited (>80%) when siRNA against AdipoR1 was injected, and the upregulatory response to RSG was completely abolished in these cells (Fig. 4, third group). Basal and RSG-stimulated AdipoR1 expression was unaltered in AdipoR2-KO cardiomyocytes (Fig. 4, fourth group). Similar to AdipoR1, AdipoR2 expression was also upregulated by RSG. Lack of APN or AdipoR1 neither altered basal AdipoR2 expression nor its upregulation by RSG (Fig. 5).

**Role of cardiomyocyte-derived APN in RSG cardioprotection and its receptor involvement.** Having demonstrated that the lack of cardiomyocyte-derived basal APN production exaggerated SI/R injury (Fig. 1), and that RSG upregulated the expression of APN and its receptors (Figs. 2–5), we further determined whether cardiomyocyte-derived APN is also biologically active in mediating RSG’s cardioprotective effects. Cardiomyocytes from WT, APN-KO, AdipoR1-KD, AdipoR2-KO, and AdipoR1-KD/AdipoR2-KO mice were treated with vehicle or RSG for 6 h as described above, followed by 3 h simulated ischemia and 12 h reperfusion. In WT cardiomyocytes, RSG pretreatment significantly reduced SI/R injury, as evidenced by significantly reduced LDH release and attenuated caspase-3 activation (Fig. 6, first group). In contrast, no significant cardioprotective effects of RSG were observed in cardiomyocytes from APN-KO mice (Fig. 6,
second group), indicating that in vitro cardioprotective effects of RSG are largely mediated by locally produced APN. Moreover, the cardioprotective effects of RSG were markedly reduced, but not completely lost, in cardiomyocytes isolated from AdipoR1-KD mice (Fig. 6, third group). Although AdipoR2 is expressed in cardiomyocytes, complete knockout of AdipoR2 had less profound effect than AdipoR1 knock down on RSG cardioprotection in this in vitro SI/R model (Fig. 6, fourth group). Finally, cardiomyocytes isolated from AdipoR1-KD/AdipoR2-KO mice responded to RSG similarly as AdipoR1-KD cardiomyocytes. These results demonstrated that increased cardiomyocyte APN production as a result of RSG treatment is largely responsible for the cardioprotective effects of RSG, and such effects are primarily mediated by AdipoR1 activation.

Role of APN in RSG anti-nitrative signaling and its receptor involvement. Our previous studies have demonstrated that in vivo systemic APN cardioprotective effects are largely mediated by its anti-oxidative/anti-nitrative effect (26). To further investigate the intracellular mechanisms responsible for cardiomyocyte-derived APN cardioprotection, the effect of manipulating APN or APN receptors on RSG anti-oxidative/anti-nitrative effect was assessed. In cardiomyocytes isolated from WT mice, SI/R caused a greater than threefold increase in cellular nitrotyrosine content, which was markedly reduced by RSG pretreatment (Fig. 7, first group). SI/R-induced cardiomyocyte nitrotyrosine overproduction was

![Graph showing effect of RSG on adiponectin receptor 2 (AdipoR2) expression in cardiomyocytes isolated from WT or gene-manipulated mice. Assays were performed 6 h after vehicle or RSG treatment. *P < 0.05 vs. vehicle in the same group; n = 14–16 wells/group with cardiomyocytes isolated from 6–8 mice.](http://ajpendo.physiology.org/)

![Graph showing effect of APN, AdipoR1, and AdipoR2 deficiency on RSG cardioprotection against SI/R injury. Cardiomyocytes were pretreated with vehicle or RSG for 6 h followed by 3 h of SI and 12 h of reperfusion. All data were normalized against mean values of their own vehicle group. *P < 0.05 and **P < 0.01 vs. vehicle in the same group; **P < 0.01 vs. WT cardiomyocytes with the same treatment; n = 14–16 wells/group with cardiomyocytes isolated from 6–8 mice.](http://ajpendo.physiology.org/)
level of locally produced APN is indeed biologically active in
obtained clear evidence that cardiomyocyte-derived APN is
derived APN remained unexplored. Ever, a critical investigation concerning the biological activity
subsequently confirmed by other investigators (4, 11). How-
cardiomyocytes are capable of producing APN, an observation
Pineiro and colleagues (22) reported that human and murine
and cardiovascular injury (1, 7, 12, 16, 23, 24). In 2005,
cocused on identifying the relationship between systemic APN
clinical and experimental studies have been completely fo-
secreted exclusively by adipocytes. As such, although APN has
neutrophils) could be responsible for gAPN generation (27).
leukocyte elastase (secreted by activated monocytes and/or
study has shown that the cleavage of full-length APN by
products of APN containing the
tide contains a signal sequence (cleaved in the mature protein)
the primary sequence of the polypep-
tide contains a signal sequence (cleaved in the mature protein)
and a nonconserved NH2-terminal domain, followed by 22
collagen repeats, and a COOH-terminal globular domain that
has structural similarities to tumor necrosis factor-α (13). Like
all collagen domain-containing proteins, full-length APN sponta-
neously forms a homotrimer basic unit. The homotrimer
self-associates through conserved NH2-terminal cysteine resi-
dues to form disulfide-linked hexamers, which further assem-
bile into high-molecular-weight forms consisting of multiple
oligomers of the basic trimer unit. A proteolytic cleavage
product of APN containing the globular COOH-terminal do-
main (gAPN) has been postulated to exist in vivo (6). A recent
study has shown that the cleavage of full-length APN by
leukocyte elastase (secreted by activated monocytes and/or
neutrophils) could be responsible for gAPN generation (27).
For many years, APN was believed to be produced and
secreted exclusively by adipocytes. As such, although APN has
been well-accepted as a potent cardioprotective molecule,
clinical and experimental studies have been completely fo-
cused on identifying the relationship between systemic APN
and cardiovascular injury (1, 7, 12, 16, 23, 24). In 2005,
Pineiro and colleagues (22) reported that human and murine
cardiomyocytes are capable of producing APN, an observation
subsequently confirmed by other investigators (4, 11). How-
ever, a critical investigation concerning the biological activity
and physiological/pathological relevance of cardiomyocyte-
derived APN remained unexplored.
Using two different approaches in our study, we have
obtained clear evidence that cardiomyocyte-derived APN is
both biologically active and pathologically relevant. First, we
have demonstrated that SI/R injury is significantly potenti-
ated in cardiomyocytes lacking APN, indicating that APN is con-
stantly produced by adult cardiomyocytes and that this basal
level of locally produced APN is indeed biologically active in
its protection of cardiomyocytes from ischemia-reperfusion
injury. Second, we have demonstrated that cardiomyocyte
APN production is upregulated by the PPARγ system, and,
more importantly, the cardioprotective effect of RSG was
completely lost in cardiomyocytes lacking APN. To our
knowledge, this is the first direct evidence demonstrating that
cardiomyocyte-derived APN is the most important molecule
mediating the cardioprotective actions of RSG, clearly making
APN of local origin a key player in pharmacological therapeu-
tic intervention success.
Currently, it is generally accepted that APN regulates cellu-
lar function by binding/activating its specific receptors. Two
types of APN receptor have been cloned (28). Whereas
AdipoR1 is abundantly expressed in muscular cells, AdipoR2 is
predominantly expressed in the liver. They belong to a new
family of membrane receptors predicted to contain seven
transmembrane domains but are structurally and topologically
distinct from G protein-coupled receptors. APN binds to the
COOH-terminal extracellular domain of AdipoR, whereas the
NH2-terminal cytoplasmic domain interacts with an adaptor
protein, APPL1 (adaptor protein-containing pleckstrin homol-
ogy domain, phosphotyrosine binding domain, and leucine
zipper motif) (18). In addition to these two receptors, T-
cadherin has been proposed to be a receptor for hexameric and
high-molecular-weight forms of APN (14). However, the bio-
logical function of APN/T-cadherin binding remains unclear,
because T-cadherin lacks an intracellular domain.
The current study raised several interesting observations
concerning APN receptors and their involvement in locally
produced APN-mediated cardioprotection. First, the absence
of APN did not alter basal expression of the APN receptor, and it
did not affect RSG-induced receptor upregulation. However,
although the absence of one of the two APN receptor types did
not affect APN expression, deficiency of both APN receptor
types significantly upregulated APN basal expression, and
potentiates RSG response. The pathological significance of
this interesting phenomenon warrants more direct investiga-
tion. Second, APN deficiency had more significant impact on
cardiomyocyte response to ischemia-reperfusion than its recep-
tors had. Specifically, under basal condition, cardiomyocytes
lacking APN, but not APN receptors, had significantly higher
tors had. Specifically, under basal condition, cardiomyocytes
lacking APN, but not APN receptors, had significantly higher
LDH release and caspase-3 activation after SI/R (Fig. 1).
Under RSG stimulatory conditions, the RSG cardioprotective
effect was completely lost in cardiomyocytes lacking APN but
not in cardiomyocytes lacking APN receptors. Precise mecha-
nisms responsible for this discrepancy cannot be addressed in
the current study. However, several possibilities exist. In the
current study, AdipoR1 siRNA caused ~80% reduction of

 significance further increased in APN-KO cardiomyocytes (Fig.
7, second group). The anti-oxidant/anti-nitrative effect of RSG
was lost in these cells, with a highly significant difference ob-
erved between RSG-treated WT vs. RSG-treated APN-KO car-
diomyocytes (P < 0.01). Neither AdipoR1-KD nor AdipoR2-KO
had significant effect on SI/R-induced nitrotyrosine overpro-
duction (Fig. 7, third to fifth group). However, the anti-oxidative/anti-
nitrative effect of RSG was abrogated in AdipoR1-KD and AdipoR1-
KD/AdipoR2-KO cardiomyocytes (Fig. 7).

DISCUSSION

APN is a protein hormone that modulates a number of
metabolic processes, including glucose regulation and fatty
acid catabolism (2, 3). The primary sequence of the polypep-
tide contains a signal sequence (cleaved in the mature protein)
and a nonconserved NH2-terminal domain, followed by 22
collagen repeats, and a COOH-terminal globular domain that
has structural similarities to tumor necrosis factor-α (13). Like
all collagen domain-containing proteins, full-length APN sponta-
neously forms a homotrimer basic unit. The homotrimer
self-associates through conserved NH2-terminal cysteine resi-
dues to form disulfide-linked hexamers, which further assem-
bile into high-molecular-weight forms consisting of multiple
oligomers of the basic trimer unit. A proteolytic cleavage
product of APN containing the globular COOH-terminal do-
main (gAPN) has been postulated to exist in vivo (6). A recent
study has shown that the cleavage of full-length APN by
leukocyte elastase (secreted by activated monocytes and/or
neutrophils) could be responsible for gAPN generation (27).
For many years, APN was believed to be produced and
secreted exclusively by adipocytes. As such, although APN has
been well-accepted as a potent cardioprotective molecule,
clinical and experimental studies have been completely fo-
cused on identifying the relationship between systemic APN
and cardiovascular injury (1, 7, 12, 16, 23, 24). In 2005,
Pineiro and colleagues (22) reported that human and murine
cardiomyocytes are capable of producing APN, an observation
subsequently confirmed by other investigators (4, 11). How-
ever, a critical investigation concerning the biological activity
and physiological/pathological relevance of cardiomyocyte-
derived APN remained unexplored.
Using two different approaches in our study, we have
obtained clear evidence that cardiomyocyte-derived APN is
both biologically active and pathologically relevant. First, we
have demonstrated that SI/R injury is significantly potenti-
ated in cardiomyocytes lacking APN, indicating that APN is con-
stantly produced by adult cardiomyocytes and that this basal
level of locally produced APN is indeed biologically active in

Fig. 7. Effect of APN, AdipoR1, and AdipoR2
deficiency on RSG-mediated anti-oxidative/an-
ti-nitrative effect in SI/R cardiomyocytes. Car-
diomyocytes were pretreated with vehicle or
RSG for 6 h followed by 3 h of SI and 12 h of
reperfusion. All data were normalized against
mean values of their own vehicle group. **P <
0.05 and ***P < 0.01 vs. vehicle in the same
group; *P < 0.05 and **P < 0.01 vs. WT
cardiomyocytes with the same treatment; n =
14–16 wells/group with cardiomyocytes iso-
lated from 6–8 mice.


AdipoR1 expression. The remaining AdipoR1 might be responsible for partial protection in AdipoR-KD cardiomyocytes. Alternatively, other APN receptors, such as T-cadherin, might be present in adult cardiomyocytes and be able to translate APN cardioprotective signaling in AdipoR1-KD/AdipoR2-KO cardiomyocytes. Finally, cardiomyocyte-derived APN may participate in cardioprotective signaling via intracellular protein–protein interaction. Additional experiments directly investigating these possibilities are currently under investigation.

Third, although AdipoR1 and AdipoR2 are known to be constitutively expressed in adult cardiomyocytes, each receptor’s relative contribution to APN cardioprotective signaling remains unclear. As shown in Figs. 6 and 7, manipulation of AdipoR1 had greater impact on RSG’s cardioprotective and anti-inflammatory/anti-nitrative actions than alteration of AdipoR2, despite the complete knockout of AdipoR2, whereas AdipoR1 was only partially (knock down) lost in cardiomyocytes studied. At least two possibilities may explain this discrepancy. First, it is possible that the cardioprotective effects of locally produced APN are primarily mediated by AdipoR1, since cardiomyocytes are AdipoR1 dominant. Second, cardiomyocyte-derived APN may contain more low-molecular-weight APN, which has high affinity to AdipoR1. Additional experiments are currently undertaken to directly address these possibilities.

In summary, our studies demonstrated for the first time that locally produced APN by cardiomyocytes is biologically active, pathologically significant, and pharmacologically important. This locally produced APN protects cardiomyocyte against ischemia-reperfusion injury primarily via paracrine/autocrine activation of AdipoR1. Furthermore, similar to circulating APN, locally produced APN protects against cardiomyocyte injury through reduction of ischemia-reperfusion-induced oxidative/nitrative stress.

GRANTS
This research was supported by National Heart, Lung, and Blood Institute Grant 2R01HL63828, American Diabetes Association Research Award 7-08-RA-98, American Heart Association Grant-in-Aid 0855554D (to X.-L. Ma), and the Emergency Medicine Foundation Career Development Grant (to W. B. Lau).

DISCLOSURES
Conflict of interest: none declared.

REFERENCES
26. Tao L, Gao E, Xiao X, Yuan Y, Li S, Christopher TA, Lopez BL, Koch W, Chan L, Goldstein BJ, Ma XL. Adiponectin cardioprotection after...

